In the event these should occur, re-evaluate the patient and institute appropriate corrective measures
Retatrutides impact on the cardiovascular system is complex and requires clinical monitoring
Are myo-inositol and myo-inositol trispyrophosphate (ITPP) the same
From a behavioral health perspective, this transition period is not merely a physiological adjustment
Your program begins with a consultation to discuss your health history, lifestyle, previous weight loss attempts, current concerns and personal goals
The cardiovascular outcomes data are not expected to be available in time for an initial NDA filing, which is consistent with regulatory precedent: the FDA can approve an obesity agent based on weight and safety data, then require post-marketing cardiovascular outcome data as a condition of approval